Hutchison MediPharma Starts US Trial of Cancer Drug

Hutchison MediPharma, the drug development arm of Hutchison China MediTech, has started a US Phase I clinical trial of sulfatinib (HMPL-012). The trial will be a dose escalation study in US patients with solid tumors. In China, HMP plans to start a Phase III trial of HMPL-012 to treat neuroendocrine tumors and a Phase Ib study to treat thyroid cancer before the end of 2015. Although HMP has partnered many of its clinical stage candidates, it retains all rights to sulfatinib. More details.... Stock Symbol: (AIM: HCM) Share this with colleagues: // //